AMPH - アムファスタ―・ファ―マシュ―ティカルズ (Amphastar Pharmaceuticals Inc.) アムファスタ―・ファ―マシュ―ティカルズ

 AMPHのチャート


 AMPHの企業情報

symbol AMPH
会社名 Amphastar Pharmaceuticals Inc (DE) (アムファスタ―・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アムファースター・ファーマシューティカルズ(Amphastar Pharmaceuticals Inc.)は専門的医薬品会社である。同社は汎用・注射・吸入製品の開発・製造・マーケティング・販売に従事する。同社は完成医薬品医薬品原薬(API)製品の2つのセグメントを運営する。完成医薬品事業はエノキサパリン、コートロシン、アンファダーゼ、ナロキソン、リドカインゼリー、クリティカルおよびノンクリティカルケア薬を製造、販売、販売する。APIセグメントは、組換えヒトインスリンおよびブタインスリンを製造・販売する。   アムファスタ―・ファ―マシュ―ティカルズは、米国の製薬会社。技術的に困難なジェネリックと独自の注射用および吸入製品を開発、製造、マ―ケティング、販売する。同社の製品は、病院や緊急のケア臨床現場で使用され、グル―プ購入組織や卸売業者を通じて販売される。また、吸入製品は、医薬品の小売業者を通じて流通。   Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.
本社所在地 11570 6th Street Rancho Cucamonga CA 91730 USA
代表者氏名 Mary Ziping Luo メアリー・ジッピン・ルオ
代表者役職名 Chief Operating Officer Chief Scientist and Chairman of the Board
電話番号 +1 909-980-9484
設立年月日 35096
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 1644人
url www.amphastar.com
nasdaq_url https://www.nasdaq.com/symbol/amph
adr_tso
EBITDA EBITDA(百万ドル) -1.46300
終値(lastsale) 18.86
時価総額(marketcap) 872396722.44
時価総額 時価総額(百万ドル) 879.79770
売上高 売上高(百万ドル) 247.75100
企業価値(EV) 企業価値(EV)(百万ドル) 881.49570
当期純利益 当期純利益(百万ドル) -14.79300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Amphastar Pharmaceuticals Inc revenues increased 6% to $129.4M. Net loss totaled $10M vs. income of $2.9M. Revenues reflect API segment increase from $2.2M to $13.1M France segment increase from $2.1M to $7.8M United States segment increase of 2% to $121.7M. Net loss reflects Research and development increase of 38% to $26.3M (expense) Other income (expense).

 AMPHのテクニカル分析


 AMPHのニュース

   Global Heparin Market to Touch a Revenue of USD 7938.6 Million by 2030; Rising Incidences of CVDs to Create Opportunities for Market Growth  2021/12/06 12:30:00 Intrado Digital Media
Key Companies Covered in the Heparin Market Research Report Are GlaxoSmithKline plc, Pfizer Inc., Aspen Holdings, Baxter International Inc., Fresenius Kabi AG, Amphastar Pharmaceuticals, Inc., Mylan N.V., Sanofi, LEO Pharma A/S, B.Braun Melsungen AG, and other key market players. Key Companies Covered in the Heparin Market Research Report Are GlaxoSmithKline plc, Pfizer Inc., Aspen Holdings, Baxter International Inc., Fresenius Kabi AG, Amphastar Pharmaceuticals, Inc., Mylan N.V., Sanofi, LEO Pharma A/S, B.Braun Melsungen AG, and other key market players.
   State of Alaska Department of Revenue Has $512,000 Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)  2021/12/02 10:48:42 Transcript Daily
State of Alaska Department of Revenue raised its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 6.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,978 shares of the companys stock after buying an additional 1,600 shares during the []
   Brokerages Expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Will Announce Quarterly Sales of $111.62 Million  2021/11/30 19:50:42 Transcript Daily
Equities research analysts expect that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will announce sales of $111.62 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Amphastar Pharmaceuticals earnings, with estimates ranging from $109.00 million to $116.39 million. Amphastar Pharmaceuticals reported sales of $95.92 million during the same quarter last year, []
   UBS Asset Management Americas Inc. Grows Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)  2021/11/25 10:56:41 Transcript Daily
UBS Asset Management Americas Inc. raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 6.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,811 shares of the companys stock after purchasing an additional 2,724 shares during the quarter. UBS Asset Management []
   Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference  2021/11/22 11:08:00 FinanzNachrichten
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Commun
   Recap: Amphastar Pharmaceuticals Q4 Earnings  2021/03/15 17:00:00 Benzinga
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share …
   Amphastar Pharmaceuticals Is it time to Buy before this week’s earning report Stock market Insights & financial analysis  2021/03/15 16:47:00 Stock Market Daily
Amphastar Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Naloxone Market - Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc.  2021/03/09 13:56:31 OpenPR
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are
   Low Molecular Weight Heparin Market – Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories  2021/03/02 07:53:20 OpenPR
Low Molecular Weight Heparin Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu,
   Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CEO Sells $483,017.30 in Stock  2021/02/08 09:36:46 Watchlist News
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CEO Jack Y. Zhang sold 25,570 shares of the business’s stock in a transaction dated Thursday, February 4th. The shares were sold at an average price of $18.89, for a total value of $483,017.30. Following the completion of the transaction, the chief executive officer now owns 2,246,988 shares in the company, […]
   Low Molecular Weight Heparin Market – Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories  2021/03/02 07:53:20 OpenPR
Low Molecular Weight Heparin Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu,
   Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CEO Sells $483,017.30 in Stock  2021/02/08 09:36:46 Watchlist News
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CEO Jack Y. Zhang sold 25,570 shares of the business’s stock in a transaction dated Thursday, February 4th. The shares were sold at an average price of $18.89, for a total value of $483,017.30. Following the completion of the transaction, the chief executive officer now owns 2,246,988 shares in the company, […]
   Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CEO Sells 37,931 Shares of Stock  2021/02/04 02:14:58 Watchlist News
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CEO Jack Y. Zhang sold 37,931 shares of the company’s stock in a transaction that occurred on Tuesday, February 2nd. The shares were sold at an average price of $18.43, for a total value of $699,068.33. Amphastar Pharmaceuticals stock traded down $0.15 during mid-day trading on Wednesday, reaching $18.42. The company’s […]
   Naloxone Market Major Players Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., and Kern Pharma, S.L.  2020/12/15 12:29:19 OpenPR
The “Naloxone Market” report gives a weighty source to assess the market and other fundamental technicalities identifying with it. The examination unveils the total assessment and veritable parts of the Naloxone Market. The research analysts provide an elaborate description of
   Earnings Scheduled For November 6, 2020  2020/11/06 08:33:52 Benzinga
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ: AY ) is likely to report quarterly earnings at $0.66 per share on revenue of $288.39 million. • AES (NYSE: AES ) is projected to report quarterly earnings at $0.43 per share on revenue of $2.70 billion. • Amphastar Pharmaceuticals (NASDAQ: AMPH ) is likely to report quarterly earnings at $0.14 per share on revenue of $91.26 million. • Assertio Holdings (NASDAQ: ASRT ) is projected to report quarterly earnings at $0.01 per share on revenue of $32.50 million. • AYRO (NASDAQ: AYRO ) is likely to report earnings for its third quarter. • Calumet Specialty (NASDAQ: CLMT ) is projected to report quarterly loss at $0.38 per share on revenue of $531.73 million. • Colony Capital (NYSE: CLNY ) is estimated to report quarterly loss at $0.20 per share on revenue of $27.25 million. • Coty (NYSE: COTY ) is likely to report quarterly loss at $0.05 per share on revenue of $1.08 billion. • Cheniere Energy Partners, LP Cheniere Energy Partners, LP Common Units (AMEX: CQP ) is estimated to report quarterly earnings at $0.

 関連キーワード  (医薬品 米国株 アムファスタ―・ファ―マシュ―ティカルズ AMPH Amphastar Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)